Anavex Life Sciences (AVXL) said Monday its marketing authorization application for blarcamesine to potentially treat Alzheimer's disease has been accepted for review by the European Medicines Agency.
The company said its application is supported by the results of a phase 2b/3 trial evaluating blarcamesine's clinical efficacy, it added.
Shares of the company were up more than 4% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.